Aslan Pharmaceuticals Pte Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aslan Pharmaceuticals Pte Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011889
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslan’s ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore.

Aslan Pharmaceuticals Pte Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Aslan Pharma Raises USD23 Million in Venture Financing 13
Aslan Pharma Raises Additional USD9 Million in Venture Financing 15
Aslan Pharma Raises USD34 Million in Series C Financing 17
Aslan Pharma Raises US$22 Million In Series B Financing 19
Aslan Pharma Raises US$12 Million In Series A Financing 21
Partnerships 22
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 22
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 23
ASLAN Pharma Enters into Agreement with ACT Genomics 24
Licensing Agreements 25
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 27
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 28
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 29
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharma For ARRY-543 30
Equity Offering 31
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd – Key Competitors 34
Aslan Pharmaceuticals Pte Ltd – Key Employees 35
Aslan Pharmaceuticals Pte Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Corporate Communications 37
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 37
May 30, 2016: ASLAN Pharmaceuticals appoints three new Non-Executive Directors 38
Feb 29, 2016: Aslan Pharmaceuticals Appoints Andrew Howden As Independent Director 39
Product News 40
04/21/2016: New Data On Aslan’s Varlitinib To Be Published At 2016 Annual Meeting Of American Society Of Cancer Oncology 40
02/23/2016: Aslan Pharmaceuticals To Present New Data On Varlitinib At Annual American Association For Cancer Research Meeting 41
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 42
Product Approvals 43
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 43
Jun 24, 2016: ASLAN receives Orphan Drug Designation for varlitinib in gastric cancer 44
Clinical Trials 45
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 45
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 46
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aslan Pharma Raises USD23 Million in Venture Financing 13
Aslan Pharma Raises Additional USD9 Million in Venture Financing 15
Aslan Pharma Raises USD34 Million in Series C Financing 17
Aslan Pharma Raises US$22 Million In Series B Financing 19
Aslan Pharma Raises US$12 Million In Series A Financing 21
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 22
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 23
ASLAN Pharma Enters into Agreement with ACT Genomics 24
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 27
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 28
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 29
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharma For ARRY-543 30
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

★海外企業調査レポート[Aslan Pharmaceuticals Pte Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dubai Electricity and Water Authority:発電所・企業SWOT分析
    Dubai Electricity and Water Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Bengal Energy Ltd (BNG):石油・ガス:M&Aディール及び事業提携情報
    Summary Bengal Energy Ltd (Bengal Energy), formerly Avery Resources Inc is an oil and gas exploration and production company that acquires, explores, and produces prospective light oil-weighted onshore assets in Australia’s Cooper Basin and India’s Cauvery Basin. The company holds interest in Toooko …
  • Renaissance Oil Corp (ROE):企業の財務・戦略的SWOT分析
    Summary Renaissance Oil Corp (Renaissance Oil), formerly San Antonio Ventures Inc is an oil and gas exploration and development company that acquires and develops high potential shale and mature fields in Mexico. The company utilizes seismic technology and advanced structural interpretation for the …
  • Pandora Media, Inc.:企業のM&A・事業提携・投資動向
    Pandora Media, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pandora Media, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報
    Summary Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company’s lead produc …
  • Telecom Egypt Company
    Telecom Egypt Company - Strategy, SWOT and Corporate Finance Report Summary Telecom Egypt Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hitachi Chemical Co Ltd (4217):企業の財務・戦略的SWOT分析
    Hitachi Chemical Co Ltd (4217) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Clariant Ltd.:企業の戦略・SWOT・財務情報
    Clariant Ltd. - Strategy, SWOT and Corporate Finance Report Summary Clariant Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sitara Chemical Industries Ltd (SITC):企業の財務・戦略的SWOT分析
    Sitara Chemical Industries Ltd (SITC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Regal Entertainment Group:企業の戦略・SWOT・財務情報
    Regal Entertainment Group - Strategy, SWOT and Corporate Finance Report Summary Regal Entertainment Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Integrity Applications Ltd-医療機器分野:企業M&A・提携分析
    Summary Integrity Applications Ltd (Integrity Applications) is a medical device company that designs, develops and commercializes non-invasive glucose monitoring devices. The company offers glucose monitoring devices and is used in ultrasonic, electromagnetic and thermal technologies to (non-invasiv …
  • Siemens Heat Transfer Technology BV:企業の戦略的SWOT分析
    Siemens Heat Transfer Technology BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Vericel Corp (VCEL):企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Klaria Pharma Holding AB (KLAR):企業の財務・戦略的SWOT分析
    Summary Klaria Pharma Holding AB (Klaria Pharma) is a pharmaceutical company. It develops fast acting medicinal products for the treatment of cannabinoids, migraine, opioid overdose, anaphylactic shock, and cancer related pain. The company’s patented drug delivery platform features is an alginate ba …
  • Shionogi Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co., Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address the unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets produc …
  • Spotless Group Holdings Ltd:企業の戦略・SWOT・財務分析
    Spotless Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Spotless Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Tech Data Corporation:企業の戦略・SWOT・財務情報
    Tech Data Corporation - Strategy, SWOT and Corporate Finance Report Summary Tech Data Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • NuVasive Inc (NUVA):企業の財務・戦略的SWOT分析
    NuVasive Inc (NUVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Arise AB (ARISE):企業の財務・戦略的SWOT分析
    Arise AB (ARISE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆